Prostate Cancer Elder Alert: LIVING WITH TREATMENT CHOICES AND OUTCOMES

Pickett, Mary; Dw, Bruner; Joseph, Angela C; Burggraf,

doi:10.3928/0098-9134-20000201-11

Cited by 9 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The questionnaire includes five functional scales (physical, role, emotional, social and cognitive functioning), three symptom scales (fatigue, pain and nausea and vomiting), a global health status/quality of life scale, and additional single items assessing dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea and financial impact. The response format comprised yes–no (1–0) questions and assessments ranging from ‘very bad’ to ‘excellent’(1–7). All scores were linearly transformed to a 0–100 scale.…”

Section: Instrumentsmentioning

confidence: 99%

See 1 more Smart Citation

Indwelling catheter treatment and health‐related quality of life in men with prostate cancer in comparison with men with benign prostatic hyperplasia

Jakobsson

2002

Scandinavian Caring Sciences

View full text Add to dashboard Cite

Experiences from indwelling urinary catheter treatment periods were studied. Little is known of what is felt from a male perspective although catheter treatment is a common pre- and postoperative measure for men with prostate cancer and benign prostatic hyperplasia (BPH). Also studied were health-related quality of life (HRQOL) and sense of coherence (SOC). Men with catheter experience (prostate cancer n = 71, BPH n = 37) were selected from a larger questionnaire study. Assessment was made with study-specific questions together with the QLQ C-30 assessing HRQOL and the SOC questionnaire measuring sense of coherence. Data reduction method was applied to study specific variables to determine problem patterns. Correlation between HRQOL and SOC was determined. Results showed similar problem patterns in men with prostate cancer and BPH: discomfort in wearing catheter (e.g. uneasiness 48.2%), practical and psychosocial difficulties in handling and wearing catheter (e.g. attaching catheter 32.4%) and discomfort at installation (e.g. pain 29.7%). There was lack of knowledge about wearing and practical handling of the catheter. Having a cancer diagnosis did not add to uneasiness or practical problems. Life quality was correlated to SOC (p

show abstract

Section: Instrumentsmentioning

confidence: 99%

“…The number of new cases of prostate cancer was 5920 in 1997 (4). A common surgical measure necessitating catheter treatment is transurethral resection of the prostate gland, TUR‐P (5).…”

Section: Introductionmentioning

confidence: 99%

Indwelling catheter treatment and health‐related quality of life in men with prostate cancer in comparison with men with benign prostatic hyperplasia

Jakobsson

2002

Scandinavian Caring Sciences

View full text Add to dashboard Cite

show abstract

“…Patients with metastatic carcinoma of the prostate are usually treated with androgen ablation therapy. After further disease progression, they may be treated with chemotherapy including docetaxel and doxorubicin (2,3).…”

Section: Introductionmentioning

confidence: 99%

Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage–Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells

Devlin¹,

Mack²,

Burich³

et al. 2008

Molecular Cancer Research

View full text Add to dashboard Cite

Abstractp53R2 is a p53-inducible ribonucleotide reductase that contributes to DNA repair by supplying deoxynucleotide triphosphate pools in response to DNA damage. In this study, we found that p53R2 was overexpressed in prostate tumor cell lines compared with immortalized prostatic epithelial cells and that the protein was induced upon DNA damage. We investigated the effects of p53R2 silencing on DNA damage in LNCaP cells (wild-type p53). Silencing p53R2 potentiated the apoptotic effects of ionizing radiation and doxorubicin treatment as shown by increased sub-G 1 content and decreased colony formation. This sensitizing effect was specific to DNA-damaging agents. Comet assay and ;-H2AX phosphorylation status showed that the decreased p53R2 levels inhibited DNA repair. Silencing p53R2 also reduced the levels of p21 WAF1/CIP1 at the posttranscriptional level, suggesting links between the p53-dependent DNA repair and cell cycle arrest pathways. Using LNCaP sublines stably expressing dominant-negative mutant p53, we found that the sensitizing effect of p53R2 silencing is mediated by p53-dependent apoptosis pathways. In the LNCaP sublines (R273H, R248W, and G245S) that have defects in inducing p53-dependent apoptosis, p53R2 silencing did not potentiate DNA damage -induced apoptosis, whereas p53R2 silencing was effective in a LNCaP subline (P151S) which retains the ability to induce p53-dependent apoptosis. This study shows that p53R2 is a potential therapeutic target that could be used to enhance the effectiveness of ionizing radiation or DNA-damaging chemotherapy in a subset of patients with prostate cancer. (Mol Cancer Res 2008;6(5):808 -18)

show abstract

“…1,2 Although this treatment has been shown to slow the growth of existing tumors, the associated suppression of testosterone to castrate levels (either medically or surgically) may cause temporary or permanent physical changes such as fatigue, functional decline, increased body fatness, and loss of lean body tissue that can reduce health-related quality of life. 1,3,4 Attenuating the effects of androgen deprivation would be desirable.…”

mentioning

confidence: 99%

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Segal

Reid

Courneya

et al. 2003

JCO

708

683

View full text Add to dashboard Cite

show abstract

Prostate Cancer Elder Alert: LIVING WITH TREATMENT CHOICES AND OUTCOMES

Cited by 9 publications

References 46 publications

Indwelling catheter treatment and health‐related quality of life in men with prostate cancer in comparison with men with benign prostatic hyperplasia

Indwelling catheter treatment and health‐related quality of life in men with prostate cancer in comparison with men with benign prostatic hyperplasia

Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage–Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Contact Info

Product

Resources

About